BioData West 2017 Brochure.PDF

Sponsored by:

26-27 April 2017Hotel Kabuki, San Francisco

HARNESSING THE POWER OF BIG DATAIN PRECISION MEDICINE

www.healthnetworkcommunications.com/biodatawest

Organised by:

http://www.healthnetworkcommunications.com/biodatawest

“Inspiring, astonishing and thought-provoking in equal measures. What an awesome event” Intel Health

Dear future delegate,

The worlds of science and technology have never been so closely intertwined. The potential and applications of bio data

are limitless. From patients tracking their own symptoms to doctors virtually assessing patient needs; from personalized

sequencing of cancer genomes to defeating aging through AI, it is safe to say the pharma industry will never be the

same again.

BioData World West 2017 is bringing scientific innovation to the forefront with tracks on:1. Genomics2. Precision Medicine3. NEW AI track put together in partnership with MerckIn San Francisco, over 200 participants will gather in the beating heart of innovative tech to discuss disruptive approaches

being used to drive drug development, personalized medicine, and inevitably, the clinic. This unique conference gathers

clinicians, bioinformaticians, pharmaceutical companies, start-ups and government policy advisors under one roof!

Our expert speaking faculty for 2017 includes:

Healthcare is joining the big data club. With the advent of high-throughput genomics, the debut of artificial intelligence,

and more, the industry is starting to tackle the futuristic era it finds itself in.

I look forward to meeting you in San Francisco on April 26 - 27, 2017.

Edward Glanville Conference Director T/ +44 (0) 207 0921196 E/ [email protected]

IN PARTNERSHIP WITH

Atul ButteDirector, Institute for Computational Health SciencesUCSF

Ronald PrzygodzkiDirectorGenomic Medicine Implementation, U.S. Department of Veterans Affairs

Sean GrimmondDirector of Research, & Bertalli Chair of Cancer MedicineUniversity of Melbourne Centre for Cancer Research

Alex ZhavoronkovCSOThe Biogerontology Research FoundationCEOInSilico Medicine Inc

Wendy RubinsteinDirector of N.I.H. Genetic Testing Registry and Senior ScientistNIH

Christina WatersCEORARE

Sean KhozinThoracic oncologist andSenior Medical OfficerF.D.A

Elizabeth BacaSenior Health Advisor Governor’s Office of Planning and ResearchState of California Governor’s Office of Planning and Research

Slava AkmaevSenior Vice President &Chief Analytics OfficerBERG Health

Jean ZenklusenDirector, The Cancer Genome Atlas, Centre for Cancer Genomics, Office of the DirectorNational Cancer Institute

Register your team online today to save! www.healthnetworkcommunications.com/biodatawest

Register online today to reserve your place! www.healthnetworkcommunications.com/biodatawest

Featured sessions include:

GENOMICS & HEALTH

“Storing and processing genome data will exceed the computing challenges running of YouTube and Twitter, biologists warn.”

The growth of global data, not only within healthcare, is one of the greatest success stories of the past 15 years. By 2020, there will be 5.200 GB of data for every person on Earth with genomic data predicted to be largest component of this data (each genome takes up 100GB.) Big Data and Genomics is transforming drug development, empowering the patient and redesigning the clinic.

Bringing big data and genomics to unlock cures for rare diseases

• Connecting millions of data points to deliver ground breaking healthcare

• Data is frozen knowledge. It’s up to us to bring the heat to melt it

• Investing in data

Elements of MVP (Million Veterans Project), where we want to go in the future, and our strategy to transform genomic efforts into the clinic.

• Building one of the world’s largest medical databases by safely collecting blood samples and health information from one million Veteran volunteers.

• How to manipulate one of the largest genomic data sets in the world

• Future use of MVP data to enhance the health of veterans

Leading Australia’s largest genome research effort into Cancer genome sequencing, transcriptome analysis of disease and development, and development of tools for genome analysis

• Focus on finding new ways to automate and sort these large and important data sets

• Understanding the molecular signature of each individual patient we can make more informed decisions

• Fostering global collaboration to defeat cancer




Scott Marshall (Noppe) BrandonSenior Consultant Open Medicine Institute

Scott KahnEx CIO VP Informatics Illumina

Nicholas MarkoFounding board member of the International Society for Chief Data Officers, Director of Neurosurgical OncologyGeisinger Health System

James Mills BarbeauAssoc. Professor, Brown University Alpert Medical School, Director of Laboratory Medicine Lifespan Academic Medical Center

Katherine ReidNutrition Researcher/Counselor Open Medicine Institute

David HausslerDistinguished Professor of Biomolecular Engineering U.C.S.C.





Martin AkermanCTO, Scientific Collaborator at CSHLEnvisagenics and Cold Spring Harbor Laboratory

Laura van ‘t VeerProfessor Laboratory Medicine and Associate Director Applied Genomics for the Cancer Center at UCSF; co-founder Agendia

Carolyn WilsonAssociate Director for ResearchFDA

Peter WhiteDirector, Division of Biomedical Informatics Cincinnati Children’s Hospital Medical Center

Jim BroachDirector of the Penn State Institute for Personalized Medicine University of Pennsylvania School of Medicine

Andreas M. KogelnikDirector, CEOOpen Medicine Institute

Jean ZenklusenDirector, The Cancer Genome Atlas, Centre for Cancer Genomics, Office of the Director National Cancer Institute

James CaiGlobal Head of Data Science Roche

Sàndor SzalmaHead of Data and Bioinformatics Takeda

Ruth MarchVP and Head Personalised Healthcare & Biomarkers AstraZeneca

Cinnamon BlossAssistant Professor UC San Diego

Kevin McKernanHead of Research Courtagen Life Sciences Inc

Aaron BlackDirector of Informatics Inova Translational Medicine Institute

Rick DeweySenior Director, Head of Translational GeneticsRegeneron Genetics Center

Daryl WaggotData Scientist, Stanford University

Keith EllistonChief Executive Officer Transmart Foundation

David Smith Professor of Laboratory Medicine and Pathology Chairman of the Technology Assessment Group Center for Individualized Medicine Mayo Clinic

Jeffrey BondLead Bioinformatician, NMTRCSpectrum Health System

Amalio TelentiMD, PhD, Chief Data ScientistHuman Longevity

Catherine BrownsteinManager, Molecular Genomics Core Facility Boston Children’s Hospital

Speakers include:


PRECISION MEDICINE

Healthcare is defined by paradigm shifts in technology.

With each new technological advance, we come one step closer to the goal of every human living a healthy life free of disease. Precision medicine has the potential to cure diseases previously thought incurable. It has the potential to enhance the quality of life for millions of patients around the world who traditional medications simply aren’t working for. It has the potential to eliminate side-effects as each drug is tailored to a specific subset of individuals. Even President Obama showcased his belief in the potential when he announced the Precision Medicine Initiative (PMI) through the NIH.

Uncover advances in precision medicine from across the globe in countries like the US, Singapore, Australia, Canada, Sweden, and Finland.

Genome Asia, sequencing 100,000 genomes across the Asian population

• Despite being >40% of the world’s population - are significantly underrepresented in current genomic studies and reference genome databases even though the unique genetic diversity prevalent in South and East Asia provides a valuable source of clinical insights

• Developing a commitment to open information

• Understand biology of disease and enable new therapeutic options which will have global impact.

Advancing precision medicine through collaboration and big data

• Innovation in the public sector to foster health through multiple projects including public-private partnerships

• Accelerating precision medicine in California

• Fostering a culture for collaboration and development

How to drive NGS into the clinic

• What are the roadblocks to driving NGS into the clinic?

• How systems are allowing for the provision of a personalized healthcare system

• The greater picture

Stephan C. SchusterResearch Director SCELSE Professor at Nanyang Technological University, Singapore

Elizabeth BacaSenior Health Advisor Governor’s Office of Planning and Research State of California Governor’s Office of Planning and Research

Wendy RubinsteinDirector of N.I.H. GeneticTesting Registry and SeniorScientistNIH


Novel sequencing-based assays as biomarkers of disease

• Prediction of novel biomarkers using big data

• Genomic technologies to identify the genetic etiology and underlying mechanisms of human disease in order to define precision therapies for diseased individuals

• Predictive genomic signatures of response to therapy, and novel sequencing-based assays as biomarkers of disease

The Big data hype: How to deliver next generation research at new depths on Migraines and Schizophrenia

• Is big data smoke and mirrors or does it really have a place in modern healthcare

• Breaking from the conscious and understanding data sets that are beyond comprehension without big data.

• Seeing the big data picture and treatment of diseases that have not been understood until the big data revolution in healthcare.

Ali TorkamaniDirector of Genome Informatics and Drug DiscoveryThe Scripps Translational Science Institute

Megan DoerrPrincipal Scientist Governance Sage Bionetworks

Aarno PalotieResearch Director Institute for Molecular Medicine Finland (FIMM)

Paul GlimsherDirector, Institute for the Interdisciplinary Study of Decision Making & Professor NYU Director Kavli HUMAN Project

Trevor Hawkins Independent Board Member & Strategy/Technology AdvisorVarious

Stephan C. SchusterResearch Director SCELSE Professor at Nanyang Technological University, Singapore

Hannah BayerChief Scientific OfficerThe Human Project

Aristides PatrinosDeputy Director for Research New York University Center for Urban Science and Progress


Speakers include:

Big Data and Genomics: Empowering citizens to share health data through mobile technolog

• Who are the past, present, and future health data stakeholders?

• What is the current state of health data sharing via mobile platforms?

• In what ways do app-mediated research studies support citizen empowerment in research?

Join them today by registering online! www.healthnetworkcommunications.com/biodatawest

PRECISION MEDICINE

Katherine ReidNutrition Researcher/CounselorOpen Medicine Institute

Daniel JonesProfessor and Vice Chair, Division of the Molecular PathologyOhio State University Comprehensive Cancer Center

Jeffrey BhasinClinical Epigenomics Leader Cleveland Clinic

David Smith Professor of Laboratory Medicine and Pathology Chairman of the Technology Assessment Group Center for Individualized Medicine Mayo Clinic


Manuel CorpasScientific LeadRepositive

Kevin FitzpatrickCEOCancer LinQ

Lyn FitzgeraldSenior Vice President, U.S & Global Development at National Comprehensive Cancer Network® National Comprehensive Cancer Network

Elizabeth NardiQuality of Oncology Care Fellow National Comprehensive Cancer Network

Wendy RubinsteinDirector of N.I.H. Genetic Testing Registry and Senior ScientistNIH

Jeanette McCarthyAdjunct Associate Professor Duke University

Natalie ThorneClinical Bioinformatics and Genomics Project Manager Melbourne Genomics Health Alliance


Gordon OkimotoCo-Director University of Hawaii Cancer Center

Claudio CariniGlobal Head Clinical Immunology and BiomarkersPfizer

Sean KhozinSenior Medical OfficerFDA


Laura PisaniAssistant Professor, Pediatrics - Medical GeneticsColumbia University Medical Center

Yuval ItanResearch Associate Rockefeller University

Laura van ‘t VeerProfessor Laboratory Medicine and Associate Director Applied Genomics for the Cancer Center, UCSF co-founder, Agendia

Marie-Pierre DubéDirector Beaulieu-Saucier Université de Montréal Pharmacogenomics Centre

Catherine BrownsteinManager Molecular Genomics Core Facility, Boston Children’s Hospital


Pravin MishraDirector, Precision Genomics Core Laboratory & R&D, Intermountain Healthcare, Dixie Regional Medical Center

John MattisonAssistant Medical Director/CMIO Kaiser Permanente


Jennifer HallChief, Institute of Precision Cardiovascular MedicineAmerican Heart Association

Ali TorkamaniDirector of Genome Informatics and Drug Discovery The Scripps Translational Science Institute

Steve MillerDirector UCSF Clinical Microbiology Laboratory

Adam GodzikDirector Sanford-Burnham Medical Research Institute

Anna BerryScientific Director of Personalized Medicine and Medical Director of Molecular Diagnostics Swedish Cancer Institute


INTRODUCING THE NEW AI TRACK

In partnership:

We have collaborated with Merck to put together an exciting additional track in 2017. We’ll be diving into the world of Artificial Intelligence and examining how this technology is changing the face of medicine.

Mark A. DePristoHead of deep learning for genetics and genomics Google

Slava AkmaevSenior Vice President & Chief Analytics Officer Berg Health

Sourav BandyopadhyayAssistant Professor UCSF

Sergio E BaranziniProfessor Weill Institute for Neurosciences UCSF

Debjit RayPostdoctoral researcher Sandia National Labs

Speakers include:


Defeating aging through genomics

• Effective antiaging methodologies through big data and genomics

• Understanding systems using genome wide association studies to allude to new mechanisms to aging.

• Treating aging as a disease

Artificial Intelligence in Drug Discovery and Aging Research

• Insilicos Next generation mechanisms for drug development using Artificial Intelligence to discover new targets.

• Breaking innovation stagnation in pharmaceuticals with AI

• Working beyond human cognition and innovation using Insilco mechanisms

Aubrey De GreyChief Science Officer and Co-FounderSens Foundation Inc

Alex Zhavoronkov(CSO, The Biogerontology Research Foundation) CEO InSilico Medicine Inc


• We review the history and taxonomy of machine learning and artificial intelligence

• We will introduce deep learning, covering both what it is and why its so exciting.

• We will then discuss in detail two concrete applications to life sciences problems:

• Calling SNP and indel variants in next-generation sequencing data

• Detection of diabetic retinopathy from fundus images of the eye

Philip NelsonDirector, Software Engineering Google

THE A-TO-Z OF BIODATA

Cinnamon BlossAssistant Professor UC San Diego

Claudio CariniGlobal Head Clinical Immunology and Biomarkers Pfizer

Daniel JonesProfessor and Vice Chair, Division of the Molecular Pathology Ohio State University Comprehensive Cancer Center


Christina WatersCEO RARE

Alex Zhavoronkov(CSO, The Biogerontology Research Foundation) CEO InSilico Medicine Inc

Ali TorkamaniDirector of Genome Informatics and Drug Discovery The Scripps Translational Science Institute


Aaron BlackDirector of Informatics Inova Translational Medicine Institute

Adam GodzikDirector Sanford-Burnham Medical Research Institute

James CaiGlobal Head of Data Science Roche

James Mills BarbeauAssoc. Professor, Brown University Alpert Medical School, Director of Laboratory Medicine Lifespan Academic Medical Center


Hannah BayerChief Scientific Officer The Human Project

Jeanette McCarthyAdjunct Associate Professor Duke University

Kevin FitzpatrickCEO Cancer LinQ

Kevin McKernanHead of Research Courtagen Life Sciences Inc

Laura PisaniAssistant Professor, Pediatrics - Medical Genetics Columbia University Medical Center

Laura van ‘t VeerProfessor Laboratory Medicine and Associate Director Applied Genomics for the Cancer Center at UCSF co-founder, Agendia

Lyn FitzgeraldSenior Vice President, U.S & Global Development at National Comprehensive Cancer Network® National Comprehensive Cancer Network

Daryl WaggotData Scientist Stanford University

Amalio Telenti MD, PhD, Chief Data Scientist Human Longevity

Jeffrey BhasinClinical Epigenomics Leader Cleveland Clinic

Manuel CorpasScientific Lead Repositive

Ronald PrzygodzkiDirector, Genomic Medicine Implementation, U.S. Department of Veterans Affairs

Olexandr Isayev Professor University of North Carolina at Chapel Hill

Paul Glimsher Director, Institute for the Interdisciplinary Study of Decision Making & Professor, NYU Director, Kavli HUMAN Project

Peter WhiteDirector, Division of Biomedical Informatics Cincinnati Children’s Hospital Medical Center

Pravin Mishra Director, Precision Genomics Core Laboratory & R&D, Intermountain Healthcare Dixie Regional Medical Center

Rick DeweySenior Director, Head of Translational Genetics Regeneron Genetics Center

Sergio E Baranzini Professor Weill Institute for Neurosciences UCSF

Slava Akmaev Senior Vice President & Chief Analytics Officer Berg Health

Sourav Bandyopadhyay Assistant Professor UCSF

Stephan C. Schuster Research Director, SCELSE Professor at Nanyang Technological University, Singapore

Steve Miller Director UCSF Clinical Microbiology Laboratory

Trevor Hawkins Independent Board Member & Strategy/Technology Advisor Various

Don’t hesitate – register now! www.healthnetworkcommunications.com/biodatawest

Debjit RayPostdoctoral researcher Sandia National Labs


Elizabeth NardiQuality of Oncology Care Fellow National Comprehensive Cancer Network

David HausslerDistinguished Professor of Biomolecular Engineering U.C.S.C.

David SmithProfessor of Laboratory Medicine and Pathology Chairman of the Technology Assessment Group Center for Individualized Medicin Mayo Clinic

Atul ButteDirector, Institute for Computational Health Sciences University of California, San Francisco

Aubrey De GreyChief Science Officer and Co-Founder Sens Foundation Inc

Andreas M. KogelnikDirector, CEO Open Medicine Institute

Anna BerryScientific Director of Personalized Medicine and Medical Director of Molecular Diagnostics Swedish Cancer Institute

Aristides PatrinosDeputy Director for Research New York University Center for Urban Science and Progress

Jennifer HallChief, Institute of Precision Cardiovascular Medicine American Heart Association

Jim Broach Director of the Penn State Institute for Personalized Medicine University of Pennsylvania School of Medicine

John MattisonAssistant Medical Director/CMIO Kaiser Permanente

Jeffrey BondLead Bioinformatician, NMTRC Spectrum Health System

Katherine ReidNutrition Researcher/Counselor Open Medicine Institute

Marie-Pierre DubéDirector Beaulieu-Saucier Université de Montréal Pharmacogenomics Centre

Martin AkermanCTO, Scientific Collaborator at CSHL Envisagenics and Cold Spring Harbor Laboratory

Gordon OkimotoCo-Director University of Hawaii Cancer Center

Carolyn Wilson Associate Director for Research FDA

Keith EllistonChief Executive Officer Transmart Foundation


Nancy Brown CEO American Heart Association

Natalie Thorne Clinical Bioinformatics and Genomics Project Manager Melbourne Genomics Health Alliance

Nicholas Marko Founding board member of the International Society for Chief Data Officers, Director of Neurosurgical Oncology Geisinger Health System

Ruth MarchVP and Head Personalised Healthcare & Biomarkers AstraZeneca

Sàndor SzalmaHead of Data and Bioinformatics Takeda

Scott KahnEx CIO VP Informatics Illumina

Scott Marshall (Noppe) BrandonSenior Consultant Open Medicine Institute

Sean Grimmond Director of Research, & Bertalli Chair of Cancer Medicine University of Melbourne Centre for Cancer Research

Sean Khozin Senior Medical Officer FDA

Wendy Rubinstein Director of N.I.H. Genetic Testing Registry and Senior Scientist NIH

Yuval Itan Research Associate Rockefeller University


DAY 1WEDNESDAY 26th APRIL 2017, SAN FRANCISCO

1/4

OPENING KEYNOTE PLENARY

08:45 Opening remarks: CHAIR: Atul Butte, Director, Institute for Computational Health Sciences, University of California, San Francisco

09:00 Bringing big data and genomics to unlock cures for rare diseases• Connecting millions of data points to deliver ground breaking healthcare• Data is frozen knowledge. It’s up to us to bring the heat to melt it• Investing in dataAtul Butte, Director, Institute for Computational Health Sciences, University of California, San Francisco

09:20 Elements of MVP (Million Veterans Project), where we want to go in the future, and our strategy to transform genomic efforts into the clinic.• Building one of the world’s largest medical databases by safely collecting blood samples and health information from one million Veteran

volunteers. • How to manipulate one of the largest genomic data sets in the world• Future use of MVP data to enhance the health of veteransRonald Przygodzki, Director, Genomic Medicine Implementation, U.S. Department of Veterans Affairs

09:40 Leading Australia’s largest genome research effort into Cancer genome sequencing, transcriptome analysis of disease and development, and development of tools for genome analysis• Focus on finding new ways to automate and sort these large and important data sets • Understanding the molecular signature of each individual patient we can make more informed decisions• Fostering global collaboration to defeat cancerSean Grimmond, Director of Research, & Bertalli Chair of Cancer Medicine, University of Melbourne Centre for Cancer Research

Speed networking and morning refreshments10:00

10:40 Facilitating a culture of responsible and effective sharing of cancer genome data

• Every disease is a rare disease at the molecular level

• Researchers will not have access to enough molecular test results for any rare disease without international data sharing

• Those of us involved in the Global Alliance for Genomics and Health are building successful mechanisms for international data sharing

David Haussler, Distinguished Professor of Biomolecular Engineering, U.C.S.C.

GENOMICS AND HEALTH

Deep learning in medicine: an introduction and applications to next-generation sequencing and disease diagnostics

• We review the history and taxonomy of machine learning and artificial intelligence

• We will introduce deep learning, covering both what it is and why its so exciting.

• Calling SNP and indel variants in next-generation sequencing data

• Detection of diabetic retinopathy from fundus images of the eye

Mark A. DePristo, Head of deep learning for genetics and genomics, Google

Philip Nelson, Director, Software Engineering, Google

ARTIFICIAL INTELLIGENCEPRECISION MEDICINE

Genome Asia, sequencing 100,000 genomes across the Asian population

• Despite being >40% of the world’s population - are significantly underrepresented in current genomic studies and reference genome databases even though the unique genetic diversity prevalent in South and East Asia provides a valuable source of clinical insights

• Developing a commitment to open information

• Understand biology of disease and enable new therapeutic options which will have global impact.

Stephan C. Schuster, Research Director, SCELSE, Professor at Nanyang Technological University, Singapore

11:00 PANEL DISCUSSION: Collaborative Scientific Innovation and Translational Medicine

Christina Waters, CEO, RARE

David Haussler, Distinguished Professor of Biomolecular Engineering, U.C.S.C.

David Smith, Professor of Laboratory Medicine and Pathology Chairman of the Technology Assessment Group Center for Individualized Medicine, Mayo Clinic

James Mills Barbeau, Assoc. Professor, Brown University Alpert Medical School, Director of Laboratory Medicine, Lifespan Academic Medical Center

Katherine Reid, Nutrition Researcher/Counselor, Open Medicine Institute

Scott Marshall (Noppe) Brandon, Senior Consultant, Open Medicine Institute

PANEL DISCUSSION: The Future of ‘Omics how they come together where these fields and technologies/trends are going why phenomics matter

Hannah Bayer, Chief Scientific Officer, The Human Project

Aristides Patrinos, Deputy Director for Research, New York University Center for Urban Science and Progress

Paul Glimsher, Director, Institute for the Interdisciplinary Study of Decision Making & Professor, NYU; Director, Kavli HUMAN Project

Trevor Hawkins, Independent Board Member & Strategy/Technology Advisor, Various


2/4

INTERACTIVE ROUNDTABLES

12:00 Cleaning E-Health records and raw data. Inventing the car before the wheel.

Scott Kahn, Ex CIO VP Informatics, Illumina

How to implement AI tools

Thomas Clozel, co-founder, OWKIN

Translation of NGS to the Clinic

Christina Waters, CEO, RAREDavid Smith, Professor of Laboratory Medicine and Pathology Chairman of the Technology Assessment Group Center for Individualized Medicine, Mayo ClinicCatherine Brownstein, Manager, Molecular Genomics Core Facility, Boston Children’s HospitalKatherine Reid, Nutrition Researcher/Counselor, Open Medicine Institute

Translating Big Data into Clinical Trial DesignsJurgen Hammer, Global Head of Data Science and Center and Head of Pharma Research and Early Development Informatics, Roche

Eric Lai, Senior Vice President, Head of Pharmacogenomics and Companion Diagnostics, Takeda

Developing innovative AI solutions for clinical research

Translating screening genomic panels in cancer into focused monitoring assays

Daniel Jones, Professor and Vice Chair, Division of the Molecular Pathology, Ohio State University Comprehensive Cancer Center

IT Infrastructure and HPC in GenomicsNicholas Marko, Founding board member of the International Society for Chief Data Officers, Director of Neurosurgical Oncology, Geisinger Health System

Defeating aging through AIHow do we drive epigenetics into the clinical practice?Jeffrey Bhasin, Clinical Epigenomics Leader, Cleveland Clinic

How to drive forwards innovation in precision medicine through collaboration.Scott Marshall (Noppe) Brandon, Senior Consultant, Open Medicine InstituteHealth System

The future of AI in pharmaceutical development

Efficient and ethical genome data sharingManuel Corpas, Scientific Lead, Repositive

Networking Lunch12:20

13:40 Uniting the translational and clinical research communities by developing an integrated i2b2/tranSMART platform in the cloud

• Sharing clinical data on a grand scale • How to create a unilateral data sharing and

collaborative system • The future of TranSMART Keith Elliston, Chief Executive Officer, Transmart Foundation

Artificial Intelligence in Drug Discovery and Aging Research

• Insilicos Next generation mechanisms for drug development using Artificial Intelligence to discover new targets.

• Breaking innovation stagnation in pharmaceuticals with AI

• Working beyond human cognition and innovation using Insilco mechanisms

Alex Zhavoronkov, (CSO, The Biogerontology Research Foundation) CEO, InSilico Medicine Inc

How to drive NGS into the clinic

• What are the roadblocks to driving NGS into the clinic?

• How systems are allowing for the provision of a personalized healthcare system

• The greater pictureWendy Rubinstein, Director of N.I.H. Genetic Testing Registry and Senior Scientist, NIH

14:00 Genomics: Improving Scientific Insights from Clinical Trials

• Advances in genome sequencing technologies have driven a dramatic increase in collecting genomics data, where genome sequencing in clinical trials is one of the fast growing applications.

• Industry-wide pain points are slowing the streamlined integration of genomics data into clinical trials.

• Clinical Trial Genomics provides at-scale, secure upload of genomics data and automated linking with study clinical data, machine-learning standardization of both data across studies, and turnkey analytics for immediately actionable hypotheses for on-going studies.

Jason Mezey, PhD, Professor of Computational Biology and Genetic Medicine, Cornell/Weill Cornell Medicine, Lead Architect of CTG, Medidata Solutions

Defeating aging through genomics

• Effective antiaging methodologies through big data and genomics

• Understanding systems using genome wide association studies to allude to new mechanisms to aging.

• Treating aging as a diseaseAubrey De Grey, Chief Science Officer and Co-Founder, Sens Foundation Inc

Big Data in Cancer Care, Hopes, Dreams and Hard Realities

• Big data has the potential to drive powerful insights in Cancer Care

• Clinical trials enroll only 3% of cancer patients, we need to learn from every patient

• Oncologists are seeking a “rapid learning system” that can democratize access to the most current clinical information.

Kevin Fitzpatrick, CEO, Cancer LinQ


3/4

14:20 New advances in RNA-therapeutics bring RNA-seq into focus

• New advances in RNA-therapeutics bring RNA-seq into focus

• RNA therapeutics are innovative drugs to modulate the splicing and stability of specific RNA sequences

• Envisagenics SpliceCoreTM is a cloud-based platform for the discovery of druggable splicing events

• SpliceCore combines RNA-seq analysis with public data and machine learning to predict disease-causing splicing events and their regulators

Martin Akerman, CTO, Scientific Collaborator at CSHL, Envisagenics and Cold Spring Harbor Laboratory

Title to be confirmed

Vijay Pande, Professor, Stanford University

“An Innovative Approach to Improve Cancer Care Through Evidence-Based Technology: NCCN and FlatIron collaborate on NCCN Outcomes Database”

• Proving oncology stakeholders, the ability to garner critical insights needed to make informed decisions

• Electronic health record (EHR) data aggregated for cancer quality and outcomes assessment

• Leveraging cancer data in a meaningful way to identify opportunities to enhance and improve care

Lyn Fitzgerald, Senior Vice President, U.S & Global Development at National Comprehensive Cancer Network®, National Comprehensive Cancer Network

Elizabeth Nardi, Quality of Oncology Care Fellow, National Comprehensive Cancer Network

14:40 New paradigms to enhance breast health through big data and genomics

• Using Big Data and Genomics to understand Germline risks developing breast cancer and triage.

• Breast cancer diagnosis and disease genomics for treatment and prognosis

Laura van ‘t Veer, Professor Laboratory Medicine and Associate Director Applied Genomics for the Cancer Center at UCSF; co-founder Agendia

AI Panel

Sponsored by

Medidata

A practical approach to precision medicine education

• Genomic literacy: Developing a minimalist curriculum for healthcare providers, i.e. teach me just what I need to know about genomics to practice precision medicine

• Skills: Incorporating practical, hands on experiences ordering tests, interpreting reports, communicating with patients

• Awareness: Providing opportunities to stay apprised of the latest applications of genomics in healthcare

Jeanette McCarthy, Adjunct Associate Professor, Duke University

15:00 Sponsored by

DxTerity

Sponsored by

ZS Associates

Afternoon refreshments15:20

15:40 FDA preparedness for “next gen sequencing”

• It/bioinformatics tools developed at FDA to support research and regulatory needs

• FDA research supporting regulatory evaluation of NGS data

• FDA’s role in Precision Medicine InitiativeCarolyn Wilson, Associate Director for Research, FDA

Sponsor Presentation Available

Do you have a solution that you would like to share with our audience?Contact Michael Shackil on +1.646.619.1809 or email: [email protected]

An Australian pathway for driving PM into the clinic.

• What are Australia’s methods for developing a data driven precision medicine strategy.

• New structures for the development of precision medicine.

• Piloting new precision medicine programs Lyn Fitzgerald, Senior Vice President, U.S & Global Development at National Comprehensive Cancer Network®, National Comprehensive Cancer Network

Natalie Thorne, Clinical Bioinformatics and Genomics Project Manager, Melbourne Genomics Health Alliance

16:00 IT infrastructure to speed the delivery of Precision medicine into the clinic

• Developing an efficient network architecture to empower research

• New requirements for the big data era • Customized working environments Jim Broach, Director of the Penn State Institute for Personalized Medicine, University of Pennsylvania School of Medicine

Title to be confirmedOlexandr Isayev, Professor, University of North Carolina at Chapel Hill

Big Data and Genomics: Empowering citizens to share health data through mobile technology

• Who are the past, present, and future health data stakeholders?

• What is the current state of health data sharing via mobile platforms?

• In what ways do app-mediated research studies support citizen empowerment in research?

Megan Doerr, Principal Scientist Governance, Sage Bionetworks

16:20 Integrative analysis of high throughput drug screening and genome-wide expression data in Neuroblastoma

• Integrative analysis of high throughput drug screening and genome-wide expression data provides for:

• Testing predictive biomarkers based on gene expression

• Development of predictive biomarkers using machine learning

Jeffrey Bond, Lead Bioinformatician, NMTRC, Spectrum Health System



A perspective for NGS based cancer diagnostics; assay development, validation and compliance in the midst of current and the future of Genomics

• Clinical trials and research while focusing on enhancing cancer care delivery

• Improving cancer outcomes through a targeted treatment approach

• How we respond to findings through personalized, cancer-specific treatment plans.

Pravin Mishra, Director, Precision Genomics Core Laboratory & R&D, Intermountain Healthcare, Dixie Regional Medical Center


4/4

16:40 How the cloud is affecting big data sharing?

• Storing communicating and tracking your personal health records

• Patient privacy and mechanisms • Data value and management with the

patient at the centerAndreas M. Kogelnik, Director, CEO, Open Medicine Institute

Supercomputing and the future of cancer

• The use of AI in drug development and manufacture

• How BERG uses artificial intelligence to analyze tissue samples and clinical data to model and understand diseases and guide drug discovery

• Understanding why AI is an overdue disruption to drive innovation and pharmaceutical development

Slava Akmaev, Senior Vice President & Chief Analytics Officer, Berg Health

Joint Analysis of Many Matrices by ITeration (JAMMIT): Tailoring precise treatment strategies for cancers

• Breaking the analysis bottleneck that has slowed the translation of the knowledge within the data to the clinic

• Development of a new algorithm that can accelerate the approval of powerful treatments for many cancers, improve clinical outcomes, and reduce costs for treating cancer

• Understanding when there is a need for specific chemotherapy based on an algorithm

Gordon Okimoto, Co-Director, University of Hawaii Cancer Center

17:00 Pooling knowledge worldwide through patient family engagement can accelerate finding therapies for rare disease, A case study

• A new framework for empowering undiagnosed and rare disease patient families to participate in translational medicine (patient families as an equal stakeholder)

• The need for global patient outreach and pooling of data in common platform for undiagnosed and rare disease

• Building global collaborations - data and research tool sharing across all stakeholders so critical/statistical amounts can be obtained

• The need for bringing together disease education for diagnosis and patient community creation, sharing of data of all stakeholders (patient families, clinicians and researchers) and lowering barrier to access research tools for the community needed to address undiagnosed and rare disease

• Scaling to other diseasesChristina Waters, CEO, RARE

From Big Data to Precision Medicine

• Challenges of applying big data to precision medicine

• Data integration and social implications• Do big data derail the progress of precision

medicine?Claudio Carini, Global Head Clinical Immunology and Biomarkers, Pfizer

Connecting tumor genomics with therapeutics through multi-dimensional network modules

• Cancer cell lines can model therapeutic responses, but only partially reflect tumor biology.

• Using MAGNETIC, a new method to integrate molecular profiling data using functional networks, we identify 219 gene modules in TCGA breast cancers that capture recurrent alterations, reveal new roles for H3K27 tri-methylation and accurately quantitate various cell types within the tumor microenvironment.

• We show that a significant portion of gene expression and methylation in tumors is poorly reproduced in cell lines due to differences in biology and microenvironment and MAGNETIC identifies therapeutic biomarkers that are robust to these differences. This work addresses a fundamental challenge in pharmacogenomics that can only be overcome by the joint analysis of patient and cell line data

Sourav Bandyopadhyay, Assistant Professor, UCSF

Networking cocktail reception

17:20

END OF CONFERENCE DAY ONE18:30

Enabling Pediatric Precision Genomics

• Rare disease research in pediatrics requires collaborative networks

• Networks need to enable institutions as well as investigators

• Academic institutions benefit from enterprise genomic data and literacy strategies

Peter White, Director, Division of Biomedical Informatics, Cincinnati Children’s Hospital Medical Center

17:40

DAY 2THURSDAY 27th APRIL 2017, SAN FRANCISCO

1/3

OPENING KEYNOTE PLENARY

08:45 Opening remarks

09:20 Advancing precision medicine through collaboration and big data• Innovation in the public sector to foster health through multiple projects including public-private partnerships • Accelerating precision medicine in California • Fostering a culture for collaboration and developmentElizabeth Baca, Senior Health Advisor Governor’s Office of Planning and Research, State of California Governor’s Office of Planning and Research

08:45 Making the journey from Big Data to Smart DataSean Khozin, Senior Medical Officer, FDA

09:40 The NCI Genomics Data Commons: making large-scale data usable• Accessing data by download is an untenable model in the large-scale genomics era• Data deposited in databases that do not update the alignment and/or calling as technology advances quickly becomes stale and unusable.• The NCI Genomics Data Commons tries to solve those issues by being a constantly updated database that will allow users to do queries online

without the need to download the bulk of the raw data.Jean Zenklusen, Director, The Cancer Genome Atlas, Centre for Cancer Genomics, Office of the Director, National Cancer Institute

Scientific Poster session and morning refreshments10:00

10:40 PANEL DISCUSSION: Data Democratization: Empowering efficient access and sharing of Data

James Cai, Global Head of Data Science, Roche

Andreas M. Kogelnik, Director, CEO, Open Medicine Institute

Sàndor Szalma, Head of Data and Bioinformatics, Takeda

GENOMICS AND HEALTH

PANEL DISCUSSION: Artificial Intelligence for Drug Discovery, Biomarker Development AI Pharmaceutical Strategy SessionTailored by Merck Pharma

ARTIFICIAL INTELLIGENCE PRECISION MEDICINE

PANEL DISCUSSION: How to drive Precision medicine into the clinic

Chaired by: Bill Barnett, CRIO, Regenstrief and IU School of Medicine, Regenstrief, Inc

Laura van ‘t Veer, Professor Laboratory Medicine and Associate Director Applied Genomics for the Cancer Center, UCSF; co-founder, Agendia

Laura Pisani, Assistant Professor, Pediatrics - Medical Genetics, Columbia University Medical Center

Marie-Pierre Dubé, Director, Beaulieu-Saucier Université de Montréal Pharmacogenomics Centre

Catherine Brownstein, Manager, Molecular Genomics Core Facility, Boston Children’s Hospital

11:20 AstraZeneca and HLI collaboration: Delivering precision medicine through the sequencing 1 million genomes

• Analyzing 500,000 DNA samples from AstraZeneca to bolster one of the most comprehensive databases of its kind

• Transforming the way medicine is practiced

• Streamlining drug development using big data.

Adam Platt, Global Head of Genomics, AstraZeneca

AI Pharmaceutical Strategy Session

Tailored by Merck Pharma

Advancing discoveries in cardiovascular precision medicine through big data

• AHA launches MY RESEARCH LEGACY - AN OPPORTUNITY FOR ALL INDIVIDUALS TO ENGAGE IN LIFE LONG LEARNING TO IMPROVE THEIR OWN HEALTH AND THE HEALTH OF THOSE AROUND THEM, through biosensors, technology and community. “the Individual”

• AHA strategic partners and the “tech platform” underneath My Research Legacy

• The data from My Research Legacy - driving towards solutions for millions of patients

Jennifer Hall, Chief, Institute of Precision Cardiovascular Medicine, American Heart Association

11.40 Understanding the non-coding genome

• How much new information do we expect from the non-coding human genome

• Why is exome sequencing not enough?• Where are the pathogenic variants in the

non-coding genome?

Amalio Telenti, MD, PhD, Chief Data Scientist, Human Longevity



Emerging Opportunities for Genomic Big Data Analytics in the Plecosystem Economy

• Critical opportunities for blockchain in Cancer Genomics: Micro-credit Accounting for data donors, institutional data users, ontology annotators, somatic read annotators, decision support algorithms etc.

• Emerging methods for early detection of onset and recurrence: The specificity/sensitivity dilemma

• Critical need for biomarkers across the plecosystem that help disambiguate isolated genomic data.

John Mattison, Assistant Medical Director/CMIO, Kaiser Permanente


Networking lunch12:00


2/3

13:20 Realizing the transformative potential of genomics in healthcare

• Multimodality genomics for translational purposes

• Graphical molecular network analysis for identification of novel disease biology

• Diagnosis and clinical care of patients with inherited cardiovascular disease

Rick Dewey, Senior Director, Head of Translational Genetics, Regeneron Genetics Center


• Is big data smoke and mirrors or does it really have a place in modern healthcare

• Breaking from the conscious and understanding data sets that are beyond comprehension without big data.

• Seeing the big data picture and treatment of diseases that have not been understood until the big data revolution in healthcare.

Aarno Palotie, Research Director, Institute for Molecular Medicine Finland (FIMM)

Big data on a network: Massive integration of domain knowledge to inform drug repurposing

• Resources spent on drug development are exorbitant. In parallel, the probabilities of a lead compound making it to clinic are minuscule.

• Developing a framework to integrate millions of experimental and clinical results in the form of a heterogeneous network, in which drugs, diseases, genes, etc are connected by mining a vast space of the entire domain knowledge.

• Using Machine learning to compute the probability that any given drug would interfere with mechanisms of a disease of interest (as a proxy for a potential therapeutic).

Sergio E Baranzini, Professor Weill Institute for Neurosciences, UCSF

13:40 Societal impacts of big data and genomics in healthcare

• Discussing how big data has measurably impacted our society.

• Describing current public attitudes to the sharing of data.

• Understanding how to develop a culture of data sharing

Cinnamon Bloss, Assistant Professor, UC San Diego

Advancing discoveries in cardiovascular precision medicine through big data

• Discovering the importance of Cardiovascular precision medicine

• The current projects that are taking center stage

• New grantsPradyot Prasoon, Business Technology Strategist, American Heart Association

Dr. Taha Kass-Hout, Former FDA’s 1st Chief Health Informatics Officer, and Director, FDA Office of Health Informatics



14:20 Design and implementation of Geisinger’s first enterprise big data platform

• Developing and managing a comprehensive enterprise data strategy

• Modern data governance strategies• Understanding the HPC landscape

in healthcare and pharmaceutical development

Nicholas Marko, Founding board member of the International Society for Chief Data Officers, Director of Neurosurgical Oncology, Geisinger Health System

Metagenomic next-generation sequencing for pathogen detection

• Unbiased detection of pathogen nucleic acid from patient samples can be achieved through metagenomic next-generation sequencing (mNGS).

• Broad-based organism detection requires new approaches to validation and results interpretation.

• This talk will discuss the precision diagnosis of infectious disease for meningitis/encephalitis using mNGS.

Steve Miller, Director, UCSF Clinical Microbiology Laboratory

Blockchain, AI and pharmaceutical developmentVerner De Biasi, Head Emerging Platforms, GSK

14:00 Big data in the clinic – entering a new legal environment

• Discussing the rapidly evolving legal and regulatory environment big data will encounter as it is integrated into clinical practice

• Describing the potential legal landmines, and techniques to avoid them

• Introducing risk management practices to minimize risk and maximize value

James Mills Barbeau, Assoc. Professor, Brown University Alpert Medical School, Director of Laboratory Medicine, Lifespan Academic Medical Center

Novel sequencing-based assays as biomarkers of disease

• Prediction of novel biomarkers using big data

• Genomic technologies to identify the genetic etiology and underlying mechanisms of human disease in order to define precision therapies for diseased individuals

• Predictive genomic signatures of response to therapy, and novel sequencing-based assays as biomarkers of disease

Ali Torkamani, Director of Genome Informatics and Drug Discovery, The Scripps Translational Science Institute



Afternoon refreshments14:40



3/3

15:20 Developing Inova’s IT infrastructure to support the collection, storage, visualization and distribution of genomic, clinical and laboratory data

• How do you handle data governance?• What infrastructure tools do you use to

acquire, quality control and visualize your data?

• Who are your key data consumers?

Aaron Black, Director of Informatics, Inova Translational Medicine Institute

Data Blitz 6 min AI startup talks.

1. Benevolent AI

2. Deep Genomics

3. Inventis

4. Atomwise

Discovering drivers of immune response to cancer discovered through ‘big data’ analysis

• 100 new genetic regions that affect the immune response to cancer.

• New directions for cancer immunology research

• Developing the DomainXplorer

Adam Godzik, Director, Sanford-Burnham Medical Research Institute

15:40 Next generation medical records, based on the human genome

• Developing approaches for the diagnosis of difficult-to-solve medical cases

• Harnessing a greater understanding of rare diseases

• Developing novel cures

Daryl Waggot, Data Scientist, Stanford University

Driving next generation diagnostics and precision medicine into the clinic

• Translational aspects of targeted therapy and molecular diagnostics.

• New software that will support next-generation sequencing panels to identify more targeted treatments for tumor types

• Effective management of large volumes of genetic data through a scalable system

Anna Berry, Scientific Director of Personalized Medicine and Medical Director of Molecular Diagnostics, Swedish Cancer Institute

16:00 Genomics and Health: Transferring the power of HPC & NGS to the clinic

• Methods for next generation diagnostics • Implications of big data in the clinic a case

study review• Big Data and ethics

Catherine Brownstein, Manager, Molecular Genomics Core Facility, Boston Children’s Hospital

When small data = big data, or the magic of transfer learning.

• Sharing and connecting deep learning algorithms algorithms to create conditions for a cross-fertilization between powerful artificial intelligence systems?

• Transfer learning to foster collaborative AI• How to bring big-data-trained deep

learning algorithms into the world of medical data

• How collaborative AI can bring new business models to create value with data

Gilles Wainrib, co-founder, OWKIN

Genetic modulators of the efficacy and safety of cardiovascular medications

• Review of the current state of genetic modulators of cardiovascular drugs

• Performing genomic studies of completed cardiovascular clinical trials

• Update on the Montreal Heart Institute genomic work with lipid trials

Marie-Pierre Dubé, Director, Beaulieu-Saucier Université de Montréal Pharmacogenomics Centre

16:20 Cannabis Strains and regulation

• Understanding the current issues with regulation in cannabis

• Producing and monitoring cannabis using databases and block chain

• Big Data and Cannabis

Kevin McKernan, Head of Research, Courtagen Life Sciences Inc

Automated Genome-Based Prediction tool for Pathogens for the prediction of complex virulence and antibiotic resistance phenotypes using high throughput sequencing data

• Detection of antibiotic resistance phenotypes using high throughput sequencing data.

• Machine learning algorithms to determine the diverse features (change in virulence genes, recombination, horizontal gene transfer, patient diagnostics).

• Pathogenic Potential and Countermeasures Targets

Debjit Ray, Postdoctoral researcher, Sandia National Labs

Finding a needle in a haystack: new approaches to discover disease-causing mutations in patients’ genomes

• The value of the whole genome rather than exome

• The human gene damage index• Filtering out false positives

Yuval Itan, Research Associate, Rockefeller University

CLOSE OF CONFERENCE16:40

200+ attendees

Over 80 speakers

50+ conference sessions

Here’s an overview of the floor plan. See the website for the most up-to-date version.

What this means for your business:Emerging science, technologies and collaborations are needed to make the necessary moves forward. As a provider of solutions to these issues, the event will provide a space for you to get in front of potential new customers from all walks of the precision medicines industry.

Your customers will be there to:• Hear insights from the world’s leading

thinkers, practitioners and process disrupters

• Evaluate and buy the latest tecnologies

• Create new partnerships and gain investment

• Have fun and do business

What a great opportunity to:• Debut new solutions

• Improve your brand awareness

• Meet new prospective clients

• Maintain relationships

Pursue, partner and have fun: • 200+ participants

• Thousands of formal and informal meetings over just three days

• 30+ scientific posters

• Career Corner recruitment zone

• Two engaging networking lunches

• Two networking drinks receptions

• Gala Dinner

Who should sponsor? Companies providing solutions in:

To exhibit, sponsor or speak at this year’s event call Michael Shackil at +1 646 619 1809 or email [email protected]

THE EXHIBITION

Data mining/analysis

Gene sequencing platforms

Implementation partners and systemsintegrators

Data storage/management

High throughput technology providers

IT infrastructure

Enterpriseresource planning

Cloud computing and hosting

ArtificialIntelligence

11

13

14

7

6

910

1 2 3 4 5

812

15

Streams 2 & 3

Stream 1

Exhibition

GARDEN LEVELLOBBY LEVEL

Register

Refreshments

Plenary Room

To exhibit, sponsor or speak call Michael Shackil at +1 646 619 1809 or email [email protected]

SUPPORTERS

FLOORPLAN

SAMPLE ATTENDEES

www.healthnetworkcommunications.com/biodatawest

http://www.healthnetworkcommunications.com/biodatawest

1. Hear from Atul Butte, Director, Institute for Computational Health Sciences, University of California, San Francisco as he presents a historic keynote on bringing Big Data and Genomics together to unlock cures for rare diseases

2. Discover how AI is changing the face of medicine with Merck

3. Witness how genomic medicine is transforming the clinic with the US Department of Veteran Affairs

4. Uncover advances in precision medicine from across the globe in countries like the US, Singapore, Australia, Canada, Sweden, and Finland

5. Learn how technology is empowering citizens to share health data through mobile technology with Megan Doerr, Principal Scientist Governance, Sage Bionetworks

6. Gain insight from pharma on the challenges of applying big data to precision medicine with Pfizer and Kaiser Permanente

7. Hear case studies on how big data can drive personalized medicine with Duke University, Melbourne Genomics Health Alliance, American Heart Association, and the Scripps Translational Science Institute

8. Collaborate with government, healthcare institutions and regulatory bodies such as the FDA, NIH, and National Cancer Institute to break down barriers to innovation and research

9. Cancer - With genomics are we one step closer to a cure? Hear the latest from University of Melbourne Centre for Cancer Research, U.C.S.C, Ohio State University Comprehensive Cancer Center, Cancer LinQ, National Comprehensive Cancer Network, National Cancer Institute and more

10. Meet, discuss research, and do business with hundreds of other industry leaders using the Jublia Networking System, where you can search not just by name and title, but by the content of their work.

Industries attending

Job titles

WHO ATTENDS

Reasons to attend:

Don’t hesitate – register now! www.healthnetworkcommunications.com/biodatawest

Pharma/Biotech

31%

Universities

9%

Charities/Associations

7%

Hospitals/Public Health

15%

Service providers

18%

Research Institutes

20%

22%

Manager

16%

VP

35%

Director

27%

Head

WEBSITEOur website is fully responsive and is updated regularly

EMAIL MARKETINGWe run a sophisticated lead generation and lead nurture campaign to our comprehensive database.

DIGITAL ADVERTISINGA comprehensive digital campaign will be run using google and facebook advertising. Re-targeting will be used extensively.

INBOUND MARKETINGOur team regularly blog on our blog, ebooks will be produced for download and lead generation.

SOCIAL MARKETINGBlog posts and event alerts are regularly posted to our dedicated facebook page, twitter feed and linkedin group. And they are posted to relevant 3rd party groups and pages.

PRESS AND 3RD PARTY CAMPAIGNWe will be partnering with leading press and media. Digital advertising, email blasts and page adverts will be placed in the run up to the event.

DIRECT SALESOur dedicated direct sales team ensures that no lead is left unconverted. As a sponsor or exhibitor at the BioData Congress West you can leverage our marketing campaign:

• Your logo will be prominent on all marketing materials• You can benefit from our inbound marketing machine and post blogs and content to the site

Our marketing campaign kicks off twelve months out and is a fully integrated digital campaign using a variety of channels:

Our marketing campaign has started. To start taking advantage of it, call Michael Shackil at +1 646 619 1809 or email [email protected]

AN INTEGRATED MARKETING CAMPAIGN FOR CLIENTS

The earlier you book, the more you’ll save.Your next steps towards building an effective presence at the event begins now.

RESERVE YOUR PLACE

Package TIER 1 TIER 2 TIER 3

Full Conference pass $1,600 $1,800 $2,000

Group of 3 $1,120 per person $1,260 per person $1,400 per person

Michael Shackil

on +1 646 619 1809 or email

[email protected]

Documents

BioData West 2017 Brochure.PDF